Validation of Hemorrhoidal Bleeding Score
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03060616|
Recruitment Status : Active, not recruiting
First Posted : February 23, 2017
Last Update Posted : March 8, 2019
The principal manifestation of hemorrhoidal disease is bleeding; however the severity evaluation is today based on prolapsus (Goligher classification) and bleeding factor is not included.
Even if there was some rare score including bleeding in literature , none of them were validated.
The aim of the study is first validation of bleeding score .
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||130 participants|
|Official Title:||Validation of Hemorrhoidal Bleeding Score|
|Actual Study Start Date :||September 1, 2016|
|Actual Primary Completion Date :||March 15, 2018|
|Estimated Study Completion Date :||June 30, 2019|
- assessment of bleeding score [ Time Frame: 1 day ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03060616
|Groupe Hospitalier Paris Saint Joseph|
|Paris, Ile-de-France, France, 75014|
|Study Director:||Hélène BEAUSSIER, Pharm-D||CRC|